EW
Edwards Lifesciences Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
89.77
▼ 0.06 (0.07%)
MARKET · —
Price
Open
89.83
Prev close
89.83
Day high
90.36
Day low
88.79
Volume
2.08M
Market cap
$51.75B
P/E (TTM)
53.45
52W range
72.30 – 96.29
Trailing performance
Returnvs SPY
1W
-1.98%
-0.6%
1M
+7.12%
+3.4%
3M
+7.92%
+4.8%
6M
+12.55%
+1.5%
YTD
+5.33%
-7.0%
1Y
+10.32%
-9.7%
3Y
+13.96%
-60.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$51.75B
Enterprise value$48.31B
Revenue (TTM)$6.51B
Gross profit$5.07B
EBITDA$2.00B
Net income$979.90M
EPS (TTM)$1.68
Free cash flow$1.23B
Total cash$4.25B
Total debt$704.40M
Book value / share$18.42
Shares outstanding576.40M
Float574.49M
Short % of float1.98%
Dividend yield—
Beta (5Y)0.85
Valuation & profitability ratios
Trailing P/E53.45
Forward P/E26.58
PEG ratio2.22
Price / sales—
Price / book4.88
EV / revenue7.42
EV / EBITDA24.20
Gross margin77.84%
Operating margin29.84%
Profit margin15.43%
Return on equity9.18%
Return on assets8.37%
Debt / equity6.57
Current ratio4.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $6.07B | $5.44B | $6.00B | $5.38B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.07B | $4.17B | $1.40B | $1.52B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.74 | 0.78 | +5.1% |
| Mar 2026 | 0.73 | 0.78 | +7.3% |
| Dec 2025 | 0.62 | 0.58 | -6.3% |
| Sep 2025 | 0.59 | 0.67 | +12.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.74 | 23 | $1.68B | +7.9% |
| Next quarter | 0.71 | 23 | $1.70B | +8.4% |
| Current year | 3.00 | 28 | $6.76B | +11.4% |
| Next year | 3.38 | 28 | $7.43B | +9.9% |
Analyst targets & ownership
Mean target$100.96
High target$110.00
Low target$84.00
Implied upside12.47%
Analyst count26
ConsensusBUY
Strong buy / Buy4 / 17
Hold7
Sell / Strong sell0 / 0
Held by insiders0.19%
Held by institutions97.11%
Institutions holding1.92K
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+254.52K
Net buying
Buy transactions
37
438.43K shares
Sell transactions
22
183.91K shares
Net transactions
+59
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | LIPPIS DANIEL J Officer |
SELL | 619 | $56.97K | Direct |
| Aug 11, 26 | LIPPIS DANIEL J Officer |
CONVERSION | 619 | $44.99K | Direct |
| Jul 30, 26 | MARKOWITZ WAYNE Officer |
SELL | 146 | $12.59K | Direct |
| Jul 28, 26 | MARKOWITZ WAYNE Officer |
SELL | 9.63K | $818.96K | Direct |
| Jul 28, 26 | MARKOWITZ WAYNE Officer |
CONVERSION | 9.63K | $712.66K | Direct |
| Jul 27, 26 | ZOVIGHIAN BERNARD J Chief Executive Officer |
SELL | 2.92K | $245.13K | Indirect |
| Jul 27, 26 | ZOVIGHIAN BERNARD J Chief Executive Officer |
STOCK | 319 | $0 | Direct |
| Jul 10, 26 | LIPPIS DANIEL J Officer |
SELL | 619 | $56.76K | Direct |
| Jul 10, 26 | LIPPIS DANIEL J Officer |
CONVERSION | 619 | $44.99K | Direct |
| Jul 9, 26 | MISTRAS THEODORA Chief Financial Officer |
STOCK | 99.92K | $0 | Direct |
| Jun 30, 26 | LIPPIS DANIEL J Officer |
SELL | 619 | $56.58K | Direct |
| Jun 30, 26 | LIPPIS DANIEL J Officer |
CONVERSION | 619 | $44.99K | Direct |
| Jun 17, 26 | ZOVIGHIAN BERNARD J Chief Executive Officer |
SELL | 523 | $45.98K | Indirect |
| May 29, 26 | DAHL ANDREW M Officer |
SELL | 567 | $48.85K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOBO DONALD E JR |
Officer | — | Sale |
CHOPRA DAVEEN |
Officer | 44.32K | Sale |
GALLAHUE KIERAN T. |
Director | 83.97K | Stock Award(Grant) |
LORANGER STEVEN R |
Director | 84.37K | Stock Award(Grant) |
MISTRAS THEODORA |
Chief Financial Officer | 99.92K | Stock Award(Grant) |
SZYMAN CATHERINE M |
Officer | 81.29K | Stock Award(Grant) |
ULLEM SCOTT B |
Chief Financial Officer | 313.06K | Conversion of Exercise of derivative security |
VALERIANI NICHOLAS J |
Director | 84.42K | Stock Award(Grant) |
WOOD LARRY L |
Officer | 207.05K | Sale |
ZOVIGHIAN BERNARD J |
Chief Executive Officer | — | Sale |
Moving averages & technicals
SMA 10
91.66
-2.06% from price
SMA 20
89.42
+0.41% from price
SMA 50
88.99
+0.90% from price
SMA 100
85.79
+4.64% from price
SMA 200
84.65
+6.07% from price
EMA 12
90.56
-0.87% from price
EMA 26
89.67
+0.11% from price
EMA 50
88.59
+1.33% from price
RSI (14)
50.6
Neutral
MACD (12,26,9)
0.88
Hist -0.03
ATR (14)
1.92
2.14% of price
Realised vol 30D
23.5%
Annualised
Bollinger upper
95.27
20, 2σ
Bollinger lower
83.58
20, 2σ
50 / 200 cross
Golden
88.99 vs 84.65
Trend bias
Above 200
+6.07%
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
23.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-13.2%
Peak to trough
Max drawdown 5Y
-54.3%
Peak to trough
ATR 14
1.92
2.14% of price
Beta (reported)
0.85
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.33
Call-heavy session
Put / call open interest
0.28
Positioning, not flow
Max pain
87.50
-2.6% from spot
ATM implied vol
32.3%
Nearest strike to spot
Skew (10% OTM)
+5.8%
Puts bid over calls
Call volume
392
Contracts, this expiry
Put volume
131
Contracts, this expiry
Heaviest call OI
100.00
2.33K contracts
Heaviest put OI
82.50
452 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
Zacks · 19h ago
Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating
MT Newswires · 1d ago
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
Simply Wall St. · 2d ago
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
Zacks · 2d ago
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
Zacks · 2d ago
Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings
Simply Wall St. · 2d ago
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
TMX Newsfile · 3d ago
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care
PR Newswire · 3d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.